Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
Figure 5
Flow cytometric analysis of CD4+ T cell activation and proliferation. (a) CD4+ T cell activation. (Left panel) Representative FACS dot plots of CD4 and CD25 surface expression in CD3/CD28 (1 : 10 bead/cell ratio) stimulated CD4+ T cells from a HV following electroporation (EP) with a miR-17 synthetic inhibitor (ImiR-17) or vehicle control (mock). The percentage of cells contained within each subset is indicated. (Right panel) Frequency of CD4+CD25+T cells in 9 independent miRNA-17 inhibition experiments. (b) CD4+ T cell proliferation. CD4+ T cells were labeled with cell trace violet proliferation dye and then placed in culture in the presence of CD3/CD28 stimulus for 72H and examined by flow cytometry. (Left panel) Representative histogram plot of cell proliferation in CD3/CD28 (1 : 10 bead/cell ratio) stimulated CD4+ T cells from a HV following electroporation (EP) with a miR-17 synthetic inhibitor (blue line) or vehicle control (mock) (red line). Proliferating CD4+T cells are depicted. (Middle panel) Frequency of proliferating CD4+ T cells in 9 independent miRNA-17 inhibition experiments. (Right panel) Frequency of proliferating CD4+ T cells from HVs versus RRMS untreated patients following CD3/CD28 stimulation (1 : 1 bead/cell ratio) (). Paired -test was used.;.
